General Cancer
Precision Medicine Implemented in the Community Oncology Setting
Technology plays a pivotal role in enhancing precision medicine within cancer care.
Read More
Fitting ADC Therapy Into the Treatment Paradigm in Advanced Bladder Cancer
At a live virtual event, Arlene O. Siefker-Radtke, MD, looked at the newer treatment strategies available for patients with advanced bladder cancer including sacituzumab govitecan.
Nivolumab With Chemotherapy Gains FDA Approval in Urothelial Cancer
Nivolumab given with cisplatin-based chemotherapy has received approval from the FDA for patients with treatment-naive unresectable or mUC.
Enfortumab Vedotin With Pembrolizumab Doubles Survival in Bladder Cancer
Enfortumab vedotin with pembrolizumab significantly improved survival outcomes compared with chemotherapy in patients with previously untreated advanced urothelial cancer.
Adjuvant Therapy in Bladder Cancer: Real-World vs Clinical Trials
Alex Chehrazi-Raffle, MD, discussed a real-world analysis of clinical characteristics of patients with bladder cancer receiving adjuvant nivolumab or chemotherapy.
Stable Health, Function in BCG-Unresponsive NMIBC With N-803 Plus BCG
Available data on patient-reported outcomes and positive interim results from QUILT 3.032 support N-803 for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.